Daniel J. George, MD, presents the case of a 65-year-old man with prostate cancer, reviews recent clinical trial data, and discusses his treatment practices.
EP. 1: Patient Profile: A 65-Year-Old Man With Prostate Cancer
Daniel J. George, MD, presents the case of a 65-year-old man with prostate cancer and offers his initial impressions.
EP. 2: Testing for BRCA Mutations and HRR Status in Prostate Cancer
Insights on when to test for BRCA mutations and HRR (homologous recombination repair) status when treating patients with prostate cancer, and whether to utilize tissue testing or ctDNA assays.
EP. 3: First-Line Therapy Options for mCRPC
An expert oncologist outlines first-line treatment options for patients with metastatic castration-resistant prostate cancer (mCRPC).
EP. 4: PROpel: Olaparib and Abiraterone for Patients with mCRPC
A comprehensive overview of the study design and findings from the PROpel trial, which looked at olaparib and abiraterone in patients with metastatic castration-resistant prostate cancer.
EP. 5: Recent PARP Inhibitor Data in Prostate Cancer
Daniel J. George, MD, discusses recent clinical trial data on the PARP inhibitors rucaparib and talazoparib for treatment of prostate cancer.
EP. 6: Treatment Considerations for PARP Inhibitors in mCRPC
An expert on prostate cancer provides insights on patients best suited for PARP inhibitor treatment and how to select and sequence therapy.
EP. 7: Role of PARP Inhibitor Plus Abiraterone for Patients With mCRPC
A medical oncologist discusses situations in which he might recommend abiraterone alongside a PARP inhibitor as first-line treatment for patients with mCRPC.
EP. 8: Non-BRCA HRD Mutations and Rechallenging with PARP Inhibitors in mCRPC
Daniel J. George, MD, provides insights on how to treat patients with prostate cancer who have pathogenic non-BRCA HRD mutations, and his approach when patients progress on a PARP inhibitor.
EP. 9: Managing Adverse Events Associated With PARP Inhibitors in Prostate Cancer
Clinical insights on managing adverse events associated with PARP inhibitor therapy in patients with prostate cancer.
EP. 10: Clinical Pearls for Community Oncologists Treating Prostate Cancer
Daniel J. George, MD, offers closing thoughts and advice to community oncologists who treat patients with prostate cancer.
2 Clarke Drive Cranbury, NJ 08512